$INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Healthcare
Sector
Biotechnology
Industry
Eric A. Adams Chem.
CEO
13
Employees
$1.56
Current Price
$1.81M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 1 | 4 | $9,224.05 | 5,951 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 6 | $10,148.05 | 6,551 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 8 | $59,548.05 | 39,051 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 2 | 27 | $1,123,250.45 | 724,329 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 2 | 27 | $1,123,250.45 | 724,329 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| May 29, 2026 | Vivo Opportunity, LLC 10% Owner | Purchase | 1,632 | $1.57 | $2,562.24 | View Details |
| Jun 4, 2026 | Vivo Opportunity, LLC 10% Owner | Purchase | 618 | $1.57 | $970.26 | View Details |
| May 21, 2026 | Vivo Opportunity, LLC 10% Owner | Purchase | 3,118 | $1.69 | $5,269.42 | View Details |
| May 29, 2026 | Vivo Opportunity, LLC 10% Owner | Purchase | 16,164 | $1.57 | $25,377.48 | View Details |
| May 19, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 68,551 | $1.60 | $109,667.89 | View Details |
| May 19, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 200,000 | $1.50 | $299,800.00 | View Details |
| May 19, 2026 | ADAR1 Capital Management, LLC 10% Owner | Purchase | 200,000 | $1.56 | $312,080.00 | View Details |
Showing 21โ27 of 27 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
4 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: